Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
alternative, Amgen, antagonist, bempegaldesleukin, Breakthrough, bring, Cardiology, care, committee, compliance, complied, concomitantly, CVR, Director, doublet, ESCC, imposed, irrevocably, lapse, maintenance, merit, moved, NaN, negotiated, nonvalvular, OAC, OS, proceed, profile, raw, regimen, SAS, smaller, sooner, successful, therefrom, trend, unconditional
Removed:
anticoagulant, constructing, Corporation, dollar, Incyte, misappropriation, newer, prejudice, private, sued, ultimate, vigorously
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10 Form of Restricted Stock Units Agreement with Five Year Vesting
- 10 Form of Restricted Stock Units Agreement with Four Year Vesting
- 10 Form of Restricted Stock Units Agreement with One Year Cliff Vesting
- 10 Form of Restricted Stock Units Agreement with Two Year Cliff Vesting
- 10 Amended Deferred Compensation Plan for Non-employee Directors
- 31 Exhibit 31.A
- 31 Exhibit 31.B
- 32 Exhibit 32.A
- 32 Exhibit 32.B
- Download Excel data file
- View Excel data file
Related press release
Associated BMY transcripts
BMY similar filings
Filing view
External links
EXHIBIT 32a
Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (the "Report"), as filed with the Securities and Exchange Commission on October 31, 2019, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.
/s/ Giovanni Caforio |
Giovanni Caforio Chairman of the Board and Chief Executive Officer |
October 31, 2019
This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Report. A signed original of this written statement required by Section 906 has been provided to Bristol-Myers Squibb Company and will be retained by Bristol-Myers Squibb Company and furnished to the Securities and Exchange Commission or its staff upon request.